How should a 60‑year‑old woman with sequential LSIL (HPV‑negative), negative colposcopy, ASC‑US (HPV‑negative), and a recent ASC‑US (HPV‑negative) 15 months later be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Sequential HPV-Negative Abnormal Cytology in a 60-Year-Old Woman

This patient should undergo cotesting (Pap + HPV) at 3-year intervals rather than returning to routine 5-year screening, and she cannot discontinue screening at age 65 based on these HPV-negative abnormal results alone. 1

Rationale for Enhanced Surveillance

The key issue here is that despite consistently negative HPV testing, this patient has had multiple abnormal cytology results (LSIL followed by two ASC-US results). This pattern places her at higher risk than women with completely negative screening histories.

Risk stratification data demonstrates:

  • HPV-negative ASC-US carries a 5-year CIN3+ risk of 1.1%, which is significantly higher than negative cotesting (0.27%) 1
  • This elevated risk persists even after negative colposcopy 1
  • Women with prior LSIL or ASC-US abnormalities require more frequent surveillance even after achieving negative HPV results 1

Specific Management Algorithm

Immediate next steps:

  • Perform cotesting (Pap + HPV) at 3-year intervals 1
  • Do not return to routine 5-year screening intervals despite negative HPV results 1

Criteria for returning to routine screening:

  • The patient must achieve either 2 consecutive negative cotests OR 3 consecutive negative Pap tests before she can return to standard 5-year intervals 1
  • This requirement applies specifically because of her history of abnormal cytology 1

Special Considerations for Age 65 and Beyond

Critical pitfall to avoid: This patient cannot discontinue screening at age 65 based on her current screening history. 1

Requirements for discontinuation:

  • She must establish adequate negative screening history (2 consecutive negative cotests or 3 consecutive negative Paps) before discontinuation can be considered 1
  • The most recent test must be within the past 5 years 2
  • Women over 65 with ASC-US should continue screening even if HPV-negative 2

Why Not Return to Routine Screening?

Although the absolute risk after HPV-negative ASC-US is relatively low (5-year CIN3+ risk of 0.54% to 1.1%), this is still 4-fold higher than after negative cotesting. 3, 1 The ASCCP consensus conference determined that this level of risk warrants enhanced surveillance with 3-year cotesting rather than routine 5-year intervals. 1

The negative colposcopy does not change this recommendation because:

  • Colposcopy has limited sensitivity for detecting all lesions 4
  • The pattern of recurrent abnormal cytology despite negative HPV suggests either sampling issues or a persistent low-grade process 1
  • Long-term surveillance is needed to ensure no progression occurs 1

Management if Future Tests Are Abnormal

If any subsequent cotest shows:

  • ASC-US or greater cytology → refer to colposcopy 4, 5
  • Positive HPV (regardless of cytology) → refer to colposcopy 4, 5
  • Both negative → continue 3-year cotesting until adequate negative history established 1

References

Guideline

Cervical Cancer Screening Guidelines for Women with LSIL/ASCUS History

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

cervical cancer screening.

Journal of the National Comprehensive Cancer Network : JNCCN, 2014

Guideline

cervical cancer screening.

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

Related Questions

What is the recommended follow-up for a patient with Low-grade Squamous Intraepithelial Lesions (LSIL) on a Pap smear?
Can a patient with a history of Low-grade Squamous Intraepithelial Lesions (LSIL) and Atypical Squamous Cells of Undetermined Significance (ASCUS) on previous Papanicolaou (PAP) tests, a negative colposcopy, and a current negative High-Risk Human Papillomavirus (HPV) test qualify for HPV testing every 5 years?
What is the next step for a patient with Atypical Squamous Cells of Undetermined Significance (ASCUS) and a positive Human Papillomavirus (HPV) test?
Can an Intrauterine Device (IUD) be placed if a Pap test result is positive for Atypical Squamous Cells of Undetermined Significance (ASCUS)?
For a 22-year-old female with a Pap (Papanicolaou) test result of LSIL (Low-grade Squamous Intraepithelial Lesion), should HPV (Human Papillomavirus) testing have been automatically reflexed by the lab?
Is a urinalysis showing positive leukocyte esterase, negative nitrite, and pyuria a normal finding in a patient with untreated Chlamydia trachomatis or Neisseria gonorrhoeae infection?
Why am I noticing melena (black specks of blood) in my stool along with rectal bleeding?
What is the recommended prednisone dosing, duration, and taper schedule for an adult (≥18 years) with chronic atopic dermatitis and no contraindications, and how does the regimen differ for children (≥2 years)?
Which pharmacologic agent is appropriate for a patient who wants to stop drinking alcohol?
How should a rectal suppository be inserted in a newborn infant?
What first‑line pain medication is recommended for an adult with fibromyalgia who has no severe renal impairment, uncontrolled hypertension, recent myocardial infarction, or substance‑misuse history?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.